EMID2 is a novel biotherapeutic for aggressive cancers identified by in vivo screening.
Cappelletto A, Alfì E, Volf N, Vu TVA, Bortolotti F, Ciucci G, Vodret S, Fantuz M, Perin M, Colliva A, et al. J Exp Clin Cancer Res. 2024 Jan 10; 43(1):15. Epub 2024 Jan 10.